Intensity Therapeutics: INVINCIBLE-4 TNBC Trial Update
Sept 10 (Reuters) - Intensity Therapeutics Inc INTS.O:
INTENSITY THERAPEUTICS REPORTS INVINCIBLE-4, PRESURGICAL TRIPLE-NEGATIVE BREAST CANCER STUDY UPDATE
INTENSITY THERAPEUTICS INC - PATHOLOGICAL COMPLETE RESPONSE OBSERVED IN FIRST PATIENT OF COHORT A
INTENSITY THERAPEUTICS INC - LOCALIZED SKIN IRRITATION OBSERVED, NEW PATIENT ENROLLMENT PAUSED
INTENSITY THERAPEUTICS INC - SIGNIFICANT NECROSIS OBSERVED AFTER TWO DOSES OF INT230-6
INTENSITY THERAPEUTICS INC - SAFETY LOOKS FAVORABLE IN COHORT A
INTENSITY THERAPEUTICS INC - EXPECT TO REINITIATE ENROLLMENT WITH MODIFIED INT230-6 DOSING REGIMEN AS SOON AS POSSIBLE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey







